Eliminating need to dilate

Article

Faster technology to be able to screen for diabetic retinopathy is a requirement as the disease is becoming more prevalent.

Faster technology to be able to screen for diabetic retinopathy is a requirement as the disease is becoming more prevalent. A new retinal imaging system has been confirmed to match or outperform fundus cameras in a recent clinical trial.

The DRIVE trial looked at 100 people with diabetes and examined the efficacy of the EasyScan (i-Optics). The performance of the system was assessed head-to-head with a fundus camera in the early diagnosis of diabetic retinopathy.

It was shown that the non-mydriatic confocal SLO technology successfully scanned all 100 patients without pharmacological dilation. Additionally, a large portion of the study group could be imaged in under 3 minutes. The results of this trial will be featured in ARVO and will add to the results of an earlier trial of the system’s imaging performance.

One of the first doctors to use the system in the US Dr Steven Squillace gave his opinion on the system. "I've worked with SLO technology for retinal evaluation over 10 years ago as part of a group practice. We saw the benefit of undilated fundus images, but also the drawback… When I heard there was a smaller version being launched, I thought it could be what I needed."

Dr Squillace has used the technology on over 100 patients and now states that he uses it exclusively for routine check ups.

If you would like to read more about the EasyScan the full article can be found in the May print issue of OTEurope.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.